Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Detection Technology, Half-yearly report 2024

By Inderes8/6/2024, 10:00 AM
Detection Technology

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Hannu Martola
00:01 - 10:00

Good afternoon, everybody. My name is Hannu Martola, and I'm the president and CEO of Detection Technology. Welcome to Detection Technology's second quarter results webcast. I'm here to announce our results through this webcast. But before starting, just briefly, what does Detection Technology do? We are the eyes of X-ray equipment. We provide our detectors to major medical, security, and industrial OEMs. You can find our products in hospitals in computed tomography equipment, at airports for security screening, and in various industrial applications, such as battery manufacturing or food scanning for manufacturing lines, and so on. I'm pleased to now report what we have achieved after the second quarter and during the second quarter. We reached the sales of €26.1 million, growing about 4%, up from 3.5% last year. In the second quarter, we reached much better profitability, at €3.3 million, which is 12.7% of our second-quarter sales. We had quite a big variation in our business units. Our industrial business unit grew really nicely by 43%. The majority of that growth is coming from a new acquisition. We acquired Hubble and their flat panels, but also, our industrial business unit grew nicely without them. There's now, like food, industrial and so on. The various industrial markets have returned to small growth in this business. However, medical sales were a disappointment, but as expected, the healthcare sector has not been very strong. Especially in China, the healthcare reform, which has been affecting the medical sales there, was still limiting the sales. However, we have now started to see some very small positive market signals, and we expect that medical will start to slowly recover. Security sales were nice at 27%. As a big business unit, it contributes significantly to our 3.5% growth. Sales were growing in all areas, especially aviation, for security screening applications. We improved quite consistently, our year-over-year result; cash flow was really strong. And what I think is very nice, is that this is the fifth consecutive quarter that the earnings have improved for Detection Technology. On net sales by quarter, slightly better than last year. We guided flat, so this is a flat plus. So, 3.5% is still above the zero level. And actually, we have to go back to 2019 since we have had this level of sales for the second. For the second quarter on EBIT, a clear step from a year-on-year numbers. Actually, in the company, we are quite pleased with this result. I think it was as expected but slightly better than expected. But we also have to note that this 12.7 is still below the midterm target that we have set, which is 15%. But for the second quarter, the sales and results were quite acceptable. By business unit: Security has now become the largest business unit of Detection Technology, representing about 44% of our total sales, followed by medical, which after a decline, accounts for 36%. And industrial now constitutes one fifth or 20% of our sales. On markets, we clearly grew in Europe, the Middle East, and Africa, largely driven by demand in security. So, there was a 56% year-on-year growth. Conversely, the Americas experienced a significant decline. There were some exceptional items that affected the Americas' sales. In the Asia Pacific, the sales were very much the same as last year, comprising 6% of the total, a bit down from the previous year. Europe, the Middle East, Africa accounted for about 30% and the Americas for 6% of the total sales. Looking at the full year, the first half was roughly just shy of €50 million, or about flat compared to last year, with a 2% growth. We are looking forward to higher growth in the second half of the year, as we have expected and informed the markets. The EBITA is 11.4, which I think is a good start for the year. For the second half, we anticipate and should observe better performance. By business units: This trend is very similar to that of the first quarter. The medical sector was heavily down due to the China healthcare reform and anti-corruption campaigns. Both the IBU and SBU saw nice growth of over 20%. By region, the Americas were down by 60%. However, Europe was up close to 40% and Asia Pacific was effectively flat, increasing by 3.2%. Regarding finances and key figures: Just a couple of items to note here. The R&D spending was about the same as last year at €3 million, constituting 11.7% of the budget. We had very nice cash flow. That amounted to €3.9 million and €6.8 million for the first half. Investments decreased after we finalized the clean room and other facilities. First half investments totaled €1.5 million, and out of that, the second quarter accounted for €350,000. Earnings per share stood at €0.15. Concerning strategy highlights: We have now finalized and established a subsidiary, a legal entity in India. We are building a service, manufacturing, and assembly site and center in India. We also finalized the old site and factory, ensuring we are now ready to make about 10% of our sales from that side during the second half. Furthermore, we continued launching a wide range of TFT panels from Harbor Imaging. That has gone as planned, including the new dynamic panels called IGZO panels. Many of the other events we have implemented include the target setting and KPI system within the company called OnePlus SCR, which is very similar to the known OKR system. Additionally, we are starting to use the sustainability reporting system called CSRD, which is due next year. Regarding sales expectations, for the industrial sector, we expect double-digit growth in the third quarter, medical to turn to slight growth after a somewhat disappointing first half, and security to also continue with double-digit growth. As a company, our full guidance is that we expect our total net sales to grow in double digits for the third quarter and also for the entire second half. Our financial targets remain the same, with at least a 10% annual growth and at least a 15% or better operating margin, EBITDA. Additionally, out of the net proceeds, dividends of 30% to 60% will be distributed. Despite some global challenges, our business outlook for the second half is quite positive, and we now expect the business to enter into double-digit growth. Although the healthcare sector in China, which is our main market, does not yet show clear signs of recovery, there are some initial signs of increasing orders and sales forecasts. The security and industrial areas, as previously mentioned, should continue to grow. This is, in a nutshell, what's currently happening. What did we accomplish in the second quarter? If there are any questions, I would be pleased to answer them.

Matrix Carnegie
10:07 - 10:29

Hi, it's Matrix Carnegie. A couple of questions to start with the US and Americas: you mentioned exceptional reasons why net sales there are down while they are up in Europe. Could you remind us what those exceptional reasons are? Are customers taking deliveries in other parts of the world?

Hannu Martola
10:29 - 11:36

Yes, the US is the world's largest market. And within the Americas, sales in the US are the most important. Even though we have some sales in South America, for example, there is very little manufacturing actually taking place in the US for most of the equipment; the special detectors are imported. But, as we measure and report our sales, it is based on where we ship and where we invoice. We have some fairly large customers in the US focused on one customer that is moving and they have built up some stock and there is some time before they start taking stock, and so on. So, this is the reason why I use the term 'exceptional'. The US and Americas sales, we believe, are now on a consecutive basis, will be improving for the third quarter and will continue improving into the fourth quarter, getting back to normal and also into the growth trajectory.

Matrix Carnegie
11:37 - 11:54

So what you're basically saying is that the growth in European sales is not just explained by weak US sales, but it's a case of US customers not taking deliveries at the moment, while others are doing quite well, actually.

Hannu Martola
11:55 - 12:07

Yes and no. Part of the sales growth in Europe, the Middle East, and Africa is actually going to the Americas, like the US market. So, both are true.

Matrix Carnegie
12:08 - 12:28

All right, thanks. Then, about the sales mix in Q2. Was it quite normal, or was it slightly better than you might expect? I mean, medical was quite a lot down. Others were up. So, was there something peculiar in the profitability?

Hannu Martola
12:28 - 13:02

I think the mix is what we've anticipated, of course, it's what you anticipate. But let's say, during the spring, at the beginning of the year, we would not have thought medical to go down by 25%. We knew that it was going down, maybe close to 20%, but it ended up being a little bit more. However, both security and especially industrial sectors performed better. We are quite pleased that now the industrial sector outside the harbor is also growing, and the markets are pulling.

Matrix Carnegie
13:03 - 13:22

But basically, the sales mix that you had does not explain in any way the margin development. So it would have been the same, even though the growth rates would have been much closer to each other. Is that right?

Hannu Martola
13:22 - 13:47

Well, the sales mix naturally always explains the margins because that's the source for the throughput and margins. But we have seen some fluctuation differences inside the business units, depending on the customers and which products we are selling. So there's more variance from that point of view, not just from the business unit itself.

Matrix Carnegie
13:49 - 14:14

I was just thinking, then, when you said that the demand for TFT flat panel detectors has been good, and since that is a new product for you, you might think that there would be some margin additions related to those revenue streams. So is that correct, or does it have the same profitability pattern as others? The older products.

Hannu Martola
14:15 - 14:40

I mean, the TFT flat-panel detectors are primarily going to industrial applications, like in China, and a little bit to medical and so on, on average. Actually, the margins are quite similar to the average margins for DT. But there are differences if you look at different applications like industrial and medical. Then if you look inside.

Matrix Carnegie
14:41 - 15:20

All right. And then in the industrial business, the growth rate was quite nice. While it was not nice in Q1, were there some exceptional circumstances in Q1, Q2 making it that good? So is it essentially something that you just happen to gather quite a lot of business in Q2, or is it something that could be replicated in the latter part of the year? I mean, do you still expect to have that kind of high growth rate going forward?

Hannu Martola
15:20 - 15:49

Well, the exception was a little bit in Q1. There was still some stock correction from last year and also the food industry, which is important for our legacy IBU, was not pulling, and now the full IBU, I think markets were more normalized than we expect these to continue. And that's why we believe the IBU will also be growing double-digit for the third quarter.

Matrix Carnegie
15:50 - 16:21

All right. Then finally, the subsidiary in Delhi. Could you describe a bit more what you are going to achieve there? So, what's the production capacity? Should it be somewhere similar to the entire auto factory amounting to 10% of your product sales, or is it larger than Hulu? And when will it be in use? And how much CapEx are you putting into it?

Hannu Martola
16:22 - 17:41

The India subsidiary, and the long-term bottom line is that India is significantly investing in infrastructure to support the country's development and growth. And that will mean a lot of investments also into security, healthcare, and industrial areas where X-ray technology is needed. From the Texas point of view. We have now established and founded a company in the New Delhi area, and we are taking it one step at a time. We are not planning to do anything massive. We are planning to do enough so that we can market and grow our sales there. At the beginning, we have a small assembly and assembly site. As we have assessed overall, there will not be a need for significant investments from today's perspective, but of course, we are continuing to monitor developments. And also, there might be some regulatory changes coming in there and so on. So we have to adapt based on the needs. The first step we want to take is to become a local player in India, meaning that we are making 'Made in India' products for the Indian markets. And then, we continue and grow the business according to the needs.

Matrix Carnegie
17:45 - 17:47

All right. That's all for me.

Unknown 1
17:50 - 18:06

From CB. Starting with China and the business outlook there. So, how did that develop during Q2, compared to your expectations prior to the quarter?

Unknown 2
18:08 - 18:09

Uh, I.

Hannu Martola
18:09 - 18:35

In the China market, for example, the security and industrial sectors performed as expected, while the medical side was somewhat less robust. Less than what we anticipated. Not very much. We expected the first and second quarters to be fairly low in Chinese healthcare.

Unknown 1
18:35 - 18:46

Do you also share the view that the outlook now for China's medical sector for H2 is slightly weaker than what you would have expected at the beginning of the year?

Hannu Martola
18:47 - 19:16

I think the second half is still probably a bit challenging in China. It will most likely be there, showing some slight growth. But that is also due to the fact that the underlying quarters are quiet for everybody, are quite sort of lowish. And then, it is a general belief that 2025 will be very strong in China.

Unknown 1
19:16 - 19:27

Okay. So do you expect that you could be able to grow also in Q4 in medical, even though the comparable will be more challenging than in Q4?

Hannu Martola
19:27 - 20:07

Yes. Our fourth quarter last year was a bit better due to some budget items in the market. Uh, so the fourth quarter was better than the third quarter last year. Uh, what I would rather say is that we look forward to the medical sector growing in the second half. Then how it's split between the quarters and so on. Uh, so we don't expect this kind of health care reform to deal out with a big bang or anything like that. It's sort of slow, let's say starting to recover slowly and then, uh, at an increasing pace, hopefully next year.

Unknown 1
20:08 - 20:20

Understand? Uh, then were all of the cost savings already visible now, now in Q2 and then speaking of the Indian subsidiary. So how much will that increase your costs?

Hannu Martola
20:21 - 21:08

We, uh, we try to be, uh, tight with the costs and, uh, with the spending. I mean, the savings that we achieved during, like, last fall and so on. They are visible. They were visible in the first quarter. And now also for the second quarter and, uh, like I said, we don't plan to do anything really big at once in India. That would drive huge cost spending nor huge investments. We plan to take one step at a time and gradually increase. Or so we must remember that we will then get income from India and we already have some nice sales in India. And we expect that to grow. And then part of the things can be then paid with the deliverables from the sales.

Unknown 1
21:09 - 21:36

Understand? Then the last one from me. Uh, there have been new liquid limits set in airports in Europe for safety detectors. Uh, due to some technical issues. So can you clarify what kind of issue this is? And are those problems related to your components and that lead to delays in investments in Europe.

Hannu Martola
21:36 - 23:59

Yeah. Thanks. So, uh, what the European Union actually announced, was it last Wednesday or Thursday that from the 1st of September, they have defined what is the maximum size of a single item, single pack of liquids in a bag. And the new definition is 100mm. One can have several of these items in a bag, but each item is a maximum of 100 millimeters. So before this, kind of like a definite specification did not exist, quite many airports, by the way, were using their own sort of restriction of 330 milliliters. And what we have understood is, this kind of scan to understand what's inside the liquid with computed tomography. Tomography is fairly complex. And it requires quite developed algorithms. To our understanding, after some tests, they found out that the results were not sufficient. Now, they have imposed temporary restrictions for the industry until the issues are resolved, which relates to the algorithms of the equipment, not to our or any of our competitors' detectors themselves. Everyone in the industry and anyone flying is restricted by these same requirements. We don't foresee that this will have any significant impact on the plans for installing CT equipment at airports. Purchasing new equipment is simply a new stipulation; the benefits of using CT are still evident. And the benefits are actually quite significant. Meaning, people can leave their laptops in, and their liquids, but only in containers of maximum 100ml. With these allowances at airports, it will mean faster passenger throughput and smoother operations. And actually, even better security at the airports.

Unknown 1
24:00 - 24:07

So, you don't expect airports to wait for the issue to be resolved before investing in new equipment?

Hannu Martola
24:07 - 24:30

No, we don't think so. Well, it's temporary. It's temporary. We don't know for sure. I mean, even if it were permanent, in our opinion, it would not have a significant impact on the need for airports to renew their technology and for passengers to enjoy a more pleasant experience being checked with computed tomography.

Unknown 1
24:30 - 24:32

All right, I understand. Thanks. That's all for me.

Walter Ross
24:36 - 24:56

Hi. Walter Ross from Danske Bank. The first question is about TFT sales. You said that they soared in Q2. Can you give any kind of indication on the percentage of year-on-year growth or what kind of share of industrial sales they were? They were significant.

Hannu Martola
24:57 - 25:31

Well, the reason for the very nice industrial sales growth, 43%, is that we did not have any TFT sales in the underlying quarter of the previous year. So in Q2 2023, we took inventory into our books starting from the 1st of July. So, starting from the third quarter. And that explains the very nice 43% growth. The majority of the growth came from TFT panels, due to the reason I explained. But there is also significant growth in the legacy EBU part.

Walter Ross
25:36 - 25:46

All right. But roughly, how much are TFT sales now as a share of the industrial segment's sales?

Hannu Martola
25:46 - 26:18

Well, we don't report it separately. And actually, part of the TFT sales is in the medical sector, and a minor part of the TFT sales is already going to medical, with the major part being industrial. What we are now working on is getting these TFT flat panel detectors approved by mid-sized and larger medical players, as well as dental players, and then that would yield higher growth, hopefully starting from late next year.

Walter Ross
26:19 - 26:37

All right. Actually, my next question kind of relates to that. So you mentioned the TFT solutions for dental imaging now. But are there any other sales outside the industrial segment within TFT solutions?

Hannu Martola
26:37 - 27:15

There is. Well, dental is the most important for the medical sector. But there are also some other applications. And then, in the industrial area, there are various applications, one very interesting and exciting application for TFT flat panel detectors is battery manufacturing. So through the battery manufacturing process, starting from the minerals and raw materials to the battery cells, then to the battery modules, and even sorting of batteries and reusing the metals and precious materials. So X-rays are needed.

Walter Ross
27:17 - 27:27

Okay. So currently, there are some sales in the medical sector already for TFT. But not in security, none at all. It's

Hannu Martola
27:27 - 27:45

Yeah. That’s interesting, actually, these TFT panels have almost no presence in security. It's, that's just how it is. There's very little application for flat panels in security lines.

Walter Ross
27:47 - 28:04

Okay. Thanks. Then, regarding the medical segment's growth expectations, you say it's going to grow in H2. But, is it more likely to be low double-digit or higher rates? Any indication of that right now?

Hannu Martola
28:04 - 28:51

I mean, we cannot say for certain, but we believe that it's going to grow. How much time will then show? I mean, there are some small signals, like the China market, which is a global hub for healthcare equipment. So, it's very difficult to gauge, we have been quite actively talking to our customers in July. It seems that nobody has a clear view. And I understood also from the major healthcare players like General Electric, Siemens, Philips, and Canon, They are the four biggest. They also gave a similar message from their second-quarter results.

Walter Ross
28:53 - 29:08

All right. Thanks. Then two quick ones still on SBU. Can you specify which markets specifically performed well or developed well in the West? In city upgrades? Any specific comments?

Hannu Martola
29:09 - 29:10

Europe and the U.S.

Walter Ross
29:11 - 29:14

Okay. But within Europe, like uh.

Hannu Martola
29:15 - 29:34

I mean, there are various, I mean, I think there was one announced, airport by airport, one in Switzerland, and it was a major event. Overall, the markets are where the seats are installed. And we are actively involved in many of these areas. So we are market leaders in computed tomography.

Walter Ross
29:37 - 30:01

All right then, maybe it's a bit of a broad question. But you also mentioned the accelerated growth in the global security market. Your view on that, uh, strengthened, uh, what are the specific reasons for that? What is driving your increased expectations there?

Hannu Martola
30:01 - 30:30

I think, uh, the big driver is when you watch the news. I'm sorry, but there are no financial webcast transcripts in your request to correct. There are a lot of concerns and a lot of things happening. Countries and governments aim to protect their citizens by employing various screening and scanning technologies, which typically involve the use of X-ray.

Walter Ross
30:33 - 30:35

All right. Uh, from me.

Unknown 3
30:42 - 31:15

I see iOS 11 from Apple. Well, you already kind of answered my question regarding the industrial segments Q2 growth rate, mainly, namely that the 43% growth was largely attributable to the BTS acquisition. But could you maybe still comment on the legacy business growth? I mean, what was the recovery like in the legacy business? Was it mainly driven by the food industry, which had been rather soft in past quarters?

Unknown 4
31:16 - 31:16

Yeah.

Hannu Martola
31:16 - 32:02

I think, yes. I mean, the big change was, namely, especially in food. The IBU, the legacy as we call it, is a set of quite different applications. One of the major factors was food, particularly during the first quarter, where the notable exceptionality was that there was some stock correction and the markets did not behave as expected during 2023. And it yielded results, with end customers holding some stock. And that was corrected during the first quarter. So now the stocks are being used up. And uh, it's back to the sort of normal business. Hello everyone, thank you for joining us today for what promises to be an insightful presentation on Detection Technology's performance for the first half of the year 2024.

Unknown 3
32:02 - 32:03

Thank you.

Unknown 5
32:06 - 32:31

You walk in on an endless corridor. Plenty of questions have been asked, but I have a couple more. Firstly, about hyper data, it seems that you are kind of gaining traction there. And right now, is everything developing in order for your plan to work, for 2025 to get the medical approvals and, you know, the bigger industrial clients?

Hannu Martola
32:32 - 33:10

Yes, I think what is very important is the yield of new products that is going as planned. And then, the internal initiatives we are undertaking involve developing the team and training, as we have actually done in August. We have a large sales training, a global training for everyone. TFT technology and how to manage sales and account leadership effectively. So, these kinds of activities are ongoing and proceeding as planned. So if we look at the finances and so on, we are on track. So we are as we planned, and what was intended is now being executed and taking place.

Unknown 5
33:12 - 33:26

If I remember correctly, you mentioned that your target is for high growth to outpace the market. I suppose that's still intact, but could you give us any more color on that? How is the crowd outlook for the coming year?

Hannu Martola
33:26 - 33:40

It's important to note that Harbour is still fairly small, which means that the percentages can show considerable variance.

Unknown 5
33:41 - 33:55

Fair enough. You mentioned that in the third quarter you expect double-digit growth in the second half. You expected double-digit growth, but do you also expect double-digit growth in the fourth quarter?

Hannu Martola
33:55 - 34:18

We expect double-digit growth in the third quarter. And then the second half, the fourth quarter, is still a bit of a question as well. I mean, how is the China healthcare market developing and so on? So that remains to be seen. Visibility for the third quarter indicates that we are expecting double-digit growth, and we anticipate maintaining double-digit growth for the full second half. Thank you.

Matrix Carnegie
34:27 - 34:48

There is no material related to Carnegie in this session. However, we can explore information regarding Detection Technology's financial performance as discussed in the webcast. One question still regarding China. Um, if we exclude the medical business, which is in a somewhat non-standard situation in China. Did Chinese business grow in the industrial and security sectors together?

Hannu Martola
34:49 - 35:21

The thing is that PT has been very much growing with the pace of the Chinese economy growth in recent years. China has therefore been quite an important market for us. During this year, actually, the importance of Chinese growth impact to our overall growth has lessened. We have actually grown more in the Western markets.

Matrix Carnegie
35:23 - 35:26

But you're essentially saying that you still experienced growth in China.

Hannu Martola
35:27 - 35:51

We must remember that we didn't have the Harbo operations last year. Sales numbers for the second quarter are available now. So, that's a significant detail. Harbo, being a Chinese company, has a lot of sales in China until we then start to sell more of those products outside of China, too.

Matrix Carnegie
35:52 - 35:52

Right.

Hannu Martola
35:53 - 35:58

But like I said, the importance of China to our growth has lessened.

Matrix Carnegie
35:59 - 36:15

Okay, but would it be true that excluding Harbo's net sales contribution, the kind of organic growth or growth without Harbo would have still resulted in growth in China?

Hannu Martola
36:16 - 36:26

If I put it this way, if one takes out the Harbo sales from our second quarter, the sales in China decreased from last year.

Matrix Carnegie
36:26 - 36:31

Okay. Thank you. Nothing further.

Hannu Martola
36:40 - 36:47

Okay, thank you for your questions. Do we have any questions from the webcast or from online participants?

Operator
36:47 - 36:49

Are there no further questions online?

Hannu Martola
36:49 - 37:02

Yes, I think we are ready to conclude right on time, and I thank the audience and viewers for your interest and attention. I wish everybody a very nice week. Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…